SeromYx and Systems Serology supporting responses to the COVID 19 pandemic.
SeromYx has established its Systems Serology assays to the SARS-CoV-2 virus, using the CR3022 mAb to SARS which cross reacts with CoV-2 and the CoV-2 S protein. Shown below: assay set-up for the CoV-2 virus to measure antibody-dependent phagocytosis (ADCP):
As with other infectious diseases, Systems Serology offers a suite of tools to support the analysis of immune correlates of vaccine protection or disease outcome, and the design of vaccine candidates and regimens or therapeutic monoclonals that deliver the desired immune function. Our tools can also help clients assess the risk of antibody-dependent disease enhancement (ADE). This phenomenon has not been seen with SARS-COV-2, but has been demonstrated in vitro with related coronaviruses (SARS, MERS) and in vivo in feline coronavirus.